ImmunityBio Inc (IBRX) concluded trading on Thursday at a closing price of $4.78, with 3.14 million shares of worth about $15.02 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 143.88% during that period and on Thursday the price saw a gain of about 4.37%. Currently the company’s common shares owned by public are about 421.57M shares, out of which, 130.69M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 14 times over the past 12 months. They bought 209,577,696 shares in 14 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of 10.90% in past 5 days and over the past one month there was a price change of 30.96%. Year-to-date (YTD), IBRX shares are showing a performance of -4.78% which increased to 27.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.21 but also hit the highest price of $6.93 during that period. The average intraday trading volume for ImmunityBio Inc shares is 3.96 million. The stock is currently trading 23.81% above its 20-day simple moving average (SMA20), while that difference is up 17.56% for SMA50 and it goes to 63.55% higher than SMA200.
ImmunityBio Inc (NASDAQ: IBRX) currently have 421.57M outstanding shares and institutions hold larger chunk of about 8.37% of that.
The stock has a current market capitalization of $3.19B and its 3Y-monthly beta is at 1.06. It has posted earnings per share of -$1.05 in the same period. It has Quick Ratio of 2.38. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 7.49% while standing at 9.88% over the month.
Analysts are in expectations that ImmunityBio Inc (IBRX) stock would likely to be making an EPS of -$0.18 in the current quarter, while forecast for next quarter EPS is -$0.16 and it is -$0.68 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.18 which is -$0.18 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.28 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 10.58% while it is estimated to increase by 26.88% in next year. EPS is likely to shrink at an annualized rate of -1.70% for next 5-years, compared to annual growth of 2.79% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on May 12, 2023 offering a Neutral rating for the stock and assigned a target price range of between $10 and $4 to it.
